Business Context and Reporting Period
Company: Greatbatch, Inc. (Note: Request metadata listed "Integer Holdings Corp," but the filing text identifies the registrant as Greatbatch, Inc.)
Filing Type: Form 10-K Annual Report
Period Ended: December 31, 2010 (52-week fiscal year)
Business Overview: Greatbatch operates in two reportable segments: Greatbatch Medical (components and devices for Cardiac Rhythm Management, Neuromodulation, Vascular Access, and Orthopaedic markets) and Electrochem Solutions (customized battery power and wireless sensing systems for industrial applications). The company serves large multinational OEMs, with four major customers accounting for 62% of 2010 sales.
Key Financial Metrics
| Metric | 2010 | 2009 |
|---|---|---|
| Total Sales | $533.4 million | $521.8 million |
| Gross Profit | $173.6 million | $166.4 million |
| Gross Margin | 32.5% | 31.9% |
| Operating Income | $69.0 million | $1.0 million |
| Net Income | $33.1 million | ($9.0 million) loss |
| Diluted EPS | $1.40 | ($0.39) |
| Cash Flow from Operations | $76.9 million | $71.8 million |
| Working Capital | $150.9 million | $119.9 million |
| Total Debt (Long-term + Current) | $220.6 million | $289.4 million |
| Cash and Equivalents | $22.9 million | $37.9 million |
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 2% to $533.4 million, driven by recoveries in Vascular Access (+6%) and Orthopaedic (+4%) segments, which offset a slight decline in the CRM/Neuromodulation segment (-1%). Electrochem sales grew 10%.
- Profitability Surge: Operating income jumped from $1.0 million in 2009 to $69.0 million in 2010. This improvement was significantly aided by a $9.5 million gain from the settlement of the Electrochem litigation, compared to a $34.5 million charge recorded in 2009.
- Margin Expansion: Gross margin improved to 32.5% from 31.9%, attributed to a favorable product mix (higher margin products) and manufacturing efficiencies, partially offset by excess capacity costs and price concessions.
- Debt Reduction: The company repaid $78.5 million of long-term debt during 2010, reducing total debt obligations significantly.
- Intangible Assets: No goodwill impairment was recorded in 2010. In contrast, 2009 included a $15.9 million write-down of trademarks and tradenames due to rebranding.
Guidance, Outlook, and Risks
2011 Outlook
- Revenue: Projected consolidated annual sales of $540 million to $560 million.
- Segment Growth: CRM/Neuromodulation expected to be flat; Vascular Access 10-20% growth; Orthopaedic 2-10% growth; Electrochem 2-5% growth.
- Adjusted EPS: Expected to range from $1.55 to $1.65 per diluted share.
- Adjusted Operating Margin: Targeted between 12.0% and 13.0%.
Management Commentary
Management highlighted the success of its diversification strategy, which reduced reliance on the CRM market (down to 57% of sales from 80% in 2007). The company is investing heavily in R&D ($45.0 million in 2010) to commercialize new systems and device products, particularly in Vascular Access. A new 80,000 sq. ft. manufacturing facility in Allen County, IN, is planned with an investment of approximately $17 million.
Risks and Contingencies
- Customer Concentration: Four customers (Boston Scientific, Johnson & Johnson, Medtronic, St. Jude Medical) accounted for 62% of 2010 revenue. Loss of any major customer would materially harm operations.
- Healthcare Reform: The Patient Protection and Affordable Care Act imposes new taxes on OEMs and may alter reimbursement rates, potentially impacting demand.
- Raw Materials: Reliance on a limited number of suppliers for critical materials (lithium, tantalum, etc.) exposes the company to price volatility and supply interruptions.
- Intangible Assets: Intangible assets represent 52% of total assets ($402.9 million). Significant impairment charges could occur if recoverability is questioned.
Investor Verification Checklist
- Customer Contracts: Verify the status of supply agreements with the top four customers, specifically the new long-term agreement with Boston Scientific and the MOU with Medtronic signed in early 2011.
- Litigation Settlement: Confirm the finality of the Electrochem litigation settlement ($25 million payment) and ensure no residual liabilities remain.
- Debt Covenants: Review the credit facility terms to ensure compliance with leverage ratios (currently 2.38:1) and interest coverage ratios (currently 12.2:1) given the debt reduction strategy.
- Intangible Asset Valuation: Assess the assumptions used for goodwill and indefinite-lived intangible asset impairment testing, given they comprise over half of the company's assets.
- Healthcare Policy Impact: Monitor regulatory developments regarding the Affordable Care Act and its specific impact on OEM pricing and reimbursement.